NCT06403488

Letrozole Dose Increments in PCOS Patients Resistant to Letrozole

Name: Clinical Trial NCT06403488
Creator: Beni-Suef University
Keywords: Polycystic Ovary Syndrome, Letrozole 2.5mg, Phase 3, drug, clinical trial, Egypt

Letrozole Dose Increments in PCOS Patients Resistant to Letrozole Ovulation Induction

Beni-Suef University·Phase 3·ClinicalTrials.gov·drugCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Polycystic Ovary Syndrome
Drug/Device/Intervention: Letrozole 2.5mg
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Beni-Suef University
Location: Banī Suwayf,Banī Suwayf, Egypt

Timeline & enrollment

Phase: Phase 3
Start date: Oct 01, 2023
End date: Jan 30, 2024
Enrollment: 102 participants

Primary outcome

ovulation rate,endometrial thickness

Summary

Objectives: To study the effect of Letrozole dose increments on ovulation rate and endometrial thickness as a primary outcomes in patients with polycystic ovary syndrome who previously resistant to letrazole conventional dose, and chemical and clinical pregnancy considered as secondary outcomes.

ICD-10 classifications

Polycystic ovarian syndromeOvarian dysfunction, unspecifiedOvarian dysfunctionOther ovarian dysfunctionNeoplasm of uncertain or unknown behaviour: Ovary

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06403488
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06403488 through Pure Global AI's free database. This Phase 3 trial is sponsored by Beni-Suef University and is currently Completed. The study focuses on Polycystic Ovary Syndrome. Target enrollment is 102 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.